• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于 MI-SYNTAX 评分的改良 logistic 临床 SYNTAX 评分在 ST 段抬高型心肌梗死患者中的应用价值。

Usefulness of updated logistic clinical SYNTAX score based on MI-SYNTAX score in patients with ST-elevation myocardial infarction.

机构信息

Heart Center; Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.

Department of Cardiology, National University of Ireland, Galway (NUIG), Galway, Ireland.

出版信息

Catheter Cardiovasc Interv. 2021 Jun 1;97(7):E919-E928. doi: 10.1002/ccd.29383. Epub 2020 Nov 11.

DOI:10.1002/ccd.29383
PMID:33175478
Abstract

OBJECTIVES

To compare the predictive performances of the prewiring, postwiring MI-SYNTAX scores, prewiring, and postwiring Updated Logistic Clinical SYNTAX score (LCSS) for 2-year all-cause mortality post percutaneous coronary intervention (PCI) in ST-elevation myocardial infarction (STEMI) patients.

BACKGROUND

In patients with STEMI and undergoing primary PCI, coronary stenosis(es) distal to the culprit lesion is often observed after the restoration of coronary flow. To address comprehensively the complex coronary anatomy in these patients, prewiring and postwiring MI-SYNTAX scores have been reported in the literature. Furthermore, to enable individualized risk estimation for long-term all-cause mortality, the Updated LCSS has been developed by combining the anatomical SYNTAX score and clinical factors.

METHODS

In the randomized GLOBAL LEADERS trial, anatomical SYNTAX score analysis was performed by an independent angiographic corelab for the first 4,000 consecutive patients as a prespecified analysis; of these, 545 presented with STEMI. The efficacy of the mortality predictions of the four scores at 2 years were evaluated based on their discrimination and calibration abilities.

RESULTS

Complete data was available in 512 patients (93.9%). When the patients were stratified into two groups based on the median of the scores, the prewiring and postwiring Updated LCSSs demonstrated that the high-score groups were associated with higher rates of 2-year all-cause mortality compared to the low-score groups (6.6 vs. 1.2%; log-rank p = .001 and 6.6 vs. 1.2%; log-rank p = .001, respectively). There were no statistically significant differences for predicting the mortality between the prewiring (area under the curve [AUC] 0.625), postwiring MI-SYNTAX score (AUC 0.614), prewiring (AUC 0.755), and postwiring Updated LCSS (AUC 0.757). In the integrated discrimination improvement (IDI), the prewiring MI-SYNTAX score had a better discrimination for the mortality than the postwiring MI-SYNTAX score (IDI -0.0082; p = .029). The four scores had acceptable calibration abilities for 2-year all-cause mortality.

CONCLUSIONS

The prewiring Updated LCSS predicts long-term all-cause mortality with clearly useful discrimination and acceptable calibration. Since the postwiring MI-SYNTAX score does not improve mortality prediction, the prewiring MI-SYNTAX score may be preferred for the 2-year mortality prediction using the Updated LCSS.

摘要

目的

比较经皮冠状动脉介入治疗(PCI)后 2 年全因死亡率的预布线、布线后 MI-SYNTAX 评分、预布线和布线后更新的逻辑临床 SYNTAX 评分(LCSS)在 ST 段抬高型心肌梗死(STEMI)患者中的预测性能。

背景

在 STEMI 患者中进行直接 PCI 时,经常在恢复冠状动脉血流后观察到罪犯病变远端的冠状动脉狭窄。为了全面解决这些患者复杂的冠状动脉解剖结构,文献中已经报道了预布线和布线后的 MI-SYNTAX 评分。此外,为了能够对长期全因死亡率进行个体化风险评估,已经通过结合解剖学 SYNTAX 评分和临床因素开发了更新的 LCSS。

方法

在随机 GLOBAL LEADERS 试验中,对前 4000 例连续患者的解剖学 SYNTAX 评分进行了独立的血管造影核心实验室分析;其中 545 例为 STEMI 患者。根据其区分度和校准能力评估了这四个评分在 2 年时预测死亡率的效果。

结果

512 例患者(93.9%)可获得完整数据。当根据评分中位数将患者分为两组时,预布线和布线后更新的 LCSS 表明,高分组与 2 年全因死亡率较高相关,而低分组则较低(6.6%比 1.2%;log-rank p=0.001 和 6.6%比 1.2%;log-rank p=0.001,分别)。在预测死亡率方面,预布线(曲线下面积[AUC]0.625)、布线后 MI-SYNTAX 评分(AUC 0.614)、预布线(AUC 0.755)和布线后更新的 LCSS(AUC 0.757)之间没有统计学上的显著差异。在综合判别改善(IDI)方面,预布线 MI-SYNTAX 评分比布线后 MI-SYNTAX 评分具有更好的死亡率判别能力(IDI -0.0082;p=0.029)。这四个评分对于 2 年全因死亡率都有可接受的校准能力。

结论

预布线更新的 LCSS 对长期全因死亡率具有明显有用的区分度和可接受的校准能力。由于布线后 MI-SYNTAX 评分不能改善死亡率预测,因此在使用更新的 LCSS 进行 2 年死亡率预测时,可能更倾向于预布线 MI-SYNTAX 评分。

相似文献

1
Usefulness of updated logistic clinical SYNTAX score based on MI-SYNTAX score in patients with ST-elevation myocardial infarction.基于 MI-SYNTAX 评分的改良 logistic 临床 SYNTAX 评分在 ST 段抬高型心肌梗死患者中的应用价值。
Catheter Cardiovasc Interv. 2021 Jun 1;97(7):E919-E928. doi: 10.1002/ccd.29383. Epub 2020 Nov 11.
2
Usefulness of the updated logistic clinical SYNTAX score after percutaneous coronary intervention in patients with prior coronary artery bypass graft surgery: Insights from the GLOBAL LEADERS trial.经皮冠状动脉介入治疗后更新的 logistic 临床 SYNTAX 评分在既往冠状动脉旁路移植术患者中的应用价值:来自 GLOBAL LEADERS 试验的结果。
Catheter Cardiovasc Interv. 2020 Nov;96(5):E516-E526. doi: 10.1002/ccd.28898. Epub 2020 Apr 15.
3
Prediction of 1-year mortality in patients with acute coronary syndromes undergoing percutaneous coronary intervention: validation of the logistic clinical SYNTAX (Synergy Between Percutaneous Coronary Interventions With Taxus and Cardiac Surgery) score.经皮冠状动脉介入治疗的急性冠状动脉综合征患者 1 年死亡率预测:Logistic 临床 SYNTAX(紫杉醇与心脏手术联合经皮冠状动脉介入治疗的协同作用)评分的验证。
JACC Cardiovasc Interv. 2013 Jul;6(7):737-45. doi: 10.1016/j.jcin.2013.04.004.
4
Association of syntax score with short-term outcomes among acute ST-elevation myocardial infarction patients undergoing primary PCI.急性ST段抬高型心肌梗死患者接受直接经皮冠状动脉介入治疗时句法评分与短期预后的相关性
Indian Heart J. 2017 Apr;69 Suppl 1(Suppl 1):S20-S23. doi: 10.1016/j.ihj.2016.08.002. Epub 2016 Aug 24.
5
Additive prognostic value of the SYNTAX score over GRACE, TIMI, ZWOLLE, CADILLAC and PAMI risk scores in patients with acute ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention.在接受直接经皮冠状动脉介入治疗的急性 ST 段抬高型心肌梗死患者中,SYNTAX 评分优于 GRACE、TIMI、ZWOLLE、CADILLAC 和 PAMI 风险评分的附加预后价值。
Int J Cardiovasc Imaging. 2013 Aug;29(6):1215-28. doi: 10.1007/s10554-013-0202-1. Epub 2013 Feb 27.
6
Usefulness of the SYNTAX score II to predict 1-year outcome in patients with primary percutaneous coronary intervention.SYNTAX评分II在预测接受直接经皮冠状动脉介入治疗患者1年预后中的应用价值
Coron Artery Dis. 2016 Sep;27(6):483-9. doi: 10.1097/MCA.0000000000000385.
7
Comparison of SYNTAX score II efficacy with SYNTAX score and TIMI risk score for predicting in-hospital and long-term mortality in patients with ST segment elevation myocardial infarction.比较SYNTAX评分II、SYNTAX评分和TIMI风险评分预测ST段抬高型心肌梗死患者住院及长期死亡率的疗效
Int J Cardiovasc Imaging. 2018 Aug;34(8):1165-1175. doi: 10.1007/s10554-018-1333-1. Epub 2018 Mar 14.
8
Comparison of long-term prognostic value of baseline SYNTAX and clinical SYNTAX scores in ST-segment elevation myocardial infarction patients with multivessel disease.ST段抬高型心肌梗死多支血管病变患者基线SYNTAX评分与临床SYNTAX评分的长期预后价值比较
Coron Artery Dis. 2016 Jun;27(4):311-8. doi: 10.1097/MCA.0000000000000365.
9
Comparison of coronary atherosclerotic disease burden between ST-elevation myocardial infarction and non-ST-elevation myocardial infarction: Non-culprit Gensini score and non-culprit SYNTAX score.比较 ST 段抬高型心肌梗死与非 ST 段抬高型心肌梗死的冠状动脉粥样硬化性疾病负担:罪犯 Gensini 评分和罪犯 SYNTAX 评分。
Clin Cardiol. 2021 Feb;44(2):238-243. doi: 10.1002/clc.23534. Epub 2020 Dec 28.
10
Validation of the updated logistic clinical SYNTAX score for all-cause mortality in the GLOBAL LEADERS trial.验证更新后的 logistic 临床 SYNTAX 评分在 GLOBAL LEADERS 试验中全因死亡率的适用性。
EuroIntervention. 2019 Aug 9;15(6):e539-e546. doi: 10.4244/EIJ-D-19-00184.

引用本文的文献

1
'Ticagrelor alone vs. dual antiplatelet therapy from 1 month after drug-eluting coronary stenting among patients with STEMI': a post hoc analysis of the randomized GLOBAL LEADERS trial.替格瑞洛单药治疗与药物洗脱冠状动脉支架置入术后 1 个月双联抗血小板治疗在 STEMI 患者中的对比:随机 GLOBAL LEADERS 试验的事后分析。
Eur Heart J Acute Cardiovasc Care. 2021 Oct 1;10(7):756-773. doi: 10.1093/ehjacc/zuab033.
2
Aspirin-free antiplatelet regimens after PCI: insights from the GLOBAL LEADERS trial and beyond.PCI 术后无阿司匹林抗血小板治疗方案:来自 GLOBAL LEADERS 试验及其他研究的见解。
Eur Heart J Cardiovasc Pharmacother. 2021 Nov 3;7(6):547-556. doi: 10.1093/ehjcvp/pvab035.